Rapid Identification of a Protein Binding Partner for the Marine Natural Product Kahalalide F by Using Reverse Chemical Proteomics (p 524-530)
Andrew M. Piggott, Peter Karuso
Published Online: Jan 25 2008 7:14AM
DOI: 10.1002/cbic.200700608
Capable chemists: Chemists are playing an ever more important role in biology through the application of small molecules to biological systems. In this paper, we combine affinity chromatography and phage display (reverse chemical proteomics), to isolate a cellular receptor for the new anticancer drug and marine natural product, kahalalide F. The results challenge biologists to uncover the significance of the interaction between the drug and its target protein.
DESPUES DE 18 AÑOS CON SOLO TOPOTECAN CON FULL APPROVAL EN EEUU COMO TREATMENT 2a LÍNE SCLC-ES ... LA USFDA ACABA DE APROBAR AL TARLATAMAB CON FULL APPROVAL ... POR LO QUE ES YA EL NEW TREATMENT STÁNDARD EN EEUU . TIENE APROBACIÓNES ACELERADAS EN CANADA , UK, COREA ... Y EN DÍAS PODRÍA ALCANZAR LA APROBACIÓN TAMBIÉN EN CHINA QUE EN JULIO 2025, LA NMPA ACEPTÓ LA SOLICITUD DE REGISTRO (NDA) PARA TARLA OTORGÁNDOLE ADEMAS LA REVISIÓN PRIORITARIA . LA EMA TAMBIÉN LO ESTÁ YA EVALUANDO .
27 febrero 2008
NeuroPharma en el 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy .
February 28, 29 – March 1, 2008
Hong Kong
Early Markers of Dementia and A-beta Modulation
Chairs: Nancy Ip and Jacques Hugon
09:00 Jacques Hugon (Paris, France)
Correlations between cognitive, memory and peripheral signalling markers in Alzheimer’s disease
09:30 Kaj Blennow (Mölndal, Sweden)
CSF and plasma biomarkers for early Alzheimer’s disease and to monitor A-beta
modulation
10:00 Ana Martinez (Madrid, Spain)
Targeting beta-amyloid through acetylcholinesterase
(Session partially supported by an educational grant from NeuroPharma, Spain)
10:30 Break
Hong Kong
Early Markers of Dementia and A-beta Modulation
Chairs: Nancy Ip and Jacques Hugon
09:00 Jacques Hugon (Paris, France)
Correlations between cognitive, memory and peripheral signalling markers in Alzheimer’s disease
09:30 Kaj Blennow (Mölndal, Sweden)
CSF and plasma biomarkers for early Alzheimer’s disease and to monitor A-beta
modulation
10:00 Ana Martinez (Madrid, Spain)
Targeting beta-amyloid through acetylcholinesterase
(Session partially supported by an educational grant from NeuroPharma, Spain)
10:30 Break
Suscribirse a:
Comentarios (Atom)